In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...

Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...

An independent study has found that Bavarian Nordic's mpox vaccine Jynneos – currently only authorised for use in adults in ...

Wave claims this is the first clinical data with a therapeutic RNA-editing drug in humans, an achievement that boosted its ...

The human skin map – which has been published in the journal Nature and is freely available here – is just one facet of the ...

Frontiers Health is back, bringing together healthcare innovators from around the world to exchange insights and discuss some ...

Pfizer is already active in the protein degrader area, having partnered with Arvinas in a $2 billion-plus deal signed in 2021 ...

Long-term considerations: While short-term forecasting remains a priority, forecasters also keep an eye on medium and ...

The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it ...

At LSX in Boston last month, editor-in-chief Jonah Comstock caught up with Dr Tadaaki Taniguchi, chief medical officer at ...

The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics ...